ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 76 citations in OpenAlex.
- The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective.Basic & clinical pharmacology & toxicology · 2026Review
- Aberrant striatal firing mediates impulsive decision-making in a mouse model of Parkinson's disease.Brain : a journal of neurology · 2026Article
- Impulsive-compulsive behaviours and striatal neuroactivity in mildly parkinsonian rats under D2/3 agonist and L-DOPA treatment.NPJ Parkinson's disease · 2025Article
- Pramipexole Hyperactivates the External Globus Pallidus and Impairs Decision-Making in a Mouse Model of Parkinson's Disease.International journal of molecular sciences · 2024Article
- Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.CNS & neurological disorders drug targets · 2024Review
- DThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- The effects of betulinic acid chronic administration on the motor, non-motor behaviors, and globus pallidus local field potential power in a rat model of hemiparkinsonism.Iranian journal of basic medical sciences · 2022Article
- The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting.Brain research bulletin · 2022Article
- Assessment of Repetitive and Compulsive Behaviors Induced by Pramipexole in Rats: Effect of Alpha-Synuclein-Induced Nigrostriatal Degeneration.Biomedicines · 2022Article
- A metabolic biomarker predicts Parkinson's disease at the early stages in patients and animal models.The Journal of clinical investigation · 2022Article
- Noradrenergic contributions to cue-driven risk-taking and impulsivity.Psychopharmacology · 2021Article
- Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents.Biomedicines · 2021Review
- Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside.Frontiers in neuroscience · 2021Review
- Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.Psychopharmacology · 2020Article
- The adverse effects of pramipexole on probability discounting are not reversed by acute DEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2020Article
- Using rodent models to understand interactions between gambling and substance use.Current opinion in behavioral sciences · 2020Article
- Increased motor impulsivity in a rat gambling task during chronic ropinirole treatment: potentiation by win-paired audiovisual cues.Psychopharmacology · 2019Article
- Examining the neurochemical underpinnings of animal models of risky choice: Methodological and analytic considerations.Experimental and clinical psychopharmacology · 2019Review
- Dopaminergic influences on risk preferences of Parkinson's disease patients.Cognitive, affective & behavioral neuroscience · 2019Article
- Impulse control disorders in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dopamine agonist pramipexole (PPX) can increase impulsiveness, and PPX therapy for neurological diseases (Parkinson's disease (PD) and restless leg syndrome) is associated with impulse control disorders (ICDs) in subpopulations of treated patients. A commonly reported ICD is pathological gambling of which risk taking is a prominent feature. Probability discounting is a measurable aspect of risk taking. We recently developed a probability discounting paradigm wherein intracranial self-stimulation (ICSS) serves as the positive reinforcer. Here we used this paradigm to determine the effects of PPX on discounting. We included assessments of a rodent model of PD, wherein 6-OHDA was injected into the dorsolateral striatum of both hemispheres, which produced persistent PD-like deficits in posture adjustment. Rats were trained to perform ICSS-mediated probability discounting, in which PD-like and control groups exhibited similar profiles. Rats were treated twice daily for 2 weeks with 2 mg/kg (±)PPX (ie, 1 mg/kg of the active form), a dose that improved lesion-induced motor deficits. In both groups, (±)PPX increased discounting; preference for the large reinforcer was enhanced 30-45% at the most uncertain probabilities. Tolerance did not develop with repeated treatments. Increased discounting subsided within 2 weeks of (±)PPX cessation, and re-exposure to (±)PPX reinstated heightened discounting. Such findings emulate the clinical scenario; therefore, ICSS for discounting assessments in rats exhibited high face validity. This model should prove useful in medication development where assessment of the propensity of a putative therapy to induce risk-taking behaviors is of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.